JointHealth™ express   February 28, 2015

Let BC PharmaCare hear “Your Voice” on certolizumab pegol

BC PharmaCare is looking for your input on the subcutaneous injection of certolizumab pegol for the treatment of psoriatic arthritis

The subcutaneous (under the skin) injection certolizumab pegol (Cimzia®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about certolizumab pegol for the treatment of psoriatic arthritis (PsA).

You can give input if you are a B.C. resident and have PsA, a caregiver to someone with PsA, or if your group represents people who live with PsA.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.

It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
  • To view the information sheet for certolizumab pegol: click here
  • For the Patient Questionnaire: click here
  • For the Caregiver Questionnaire: click here
  • For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)
The submission deadline is midnight on March 18, 2015. Patients and caregivers may give their input directly through the links above.

Alternatively, you can email us your input at or call us at 604-974-1366. We can send it as a patient group on your behalf. Please provide your input to us by Monday, March 16 so that we may submit the questionnaire in time for the deadline.

About certolizumab pegol
Certolizumab pegol has a Health Canada indication for use in combination with methotrexate for reducing signs and symptoms, inducing major clinical response, and reducing the progression of joint damage as assessed by x-ray, in adult patients with moderately to severely active rheumatoid arthritis. It may be used alone for reducing signs and symptoms in patients with moderately to severely active rheumatoid arthritis who do not tolerate methotrexate.

About psoriatic arthritis
Psoriatic arthritis is a form of inflammatory arthritis which causes swelling and pain in and around joints, as well as a scaly rash on the skin. Joints most commonly affected are the fingers, wrists, toes, knees, shoulders, elbows, and ankles. Psoriatic arthritis affects men and women in equal numbers, and like many forms of inflammatory arthritis, it tends to strike people in the prime of their lives; most commonly, people are diagnosed between the ages of 20 and 50.